A multi‐institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer

The purpose of this study was to evaluate preoperative treatment with full‐dose gemcitabine, oxaliplatin, and radiation therapy (RT) in patients with localized pancreatic cancer.

[1]  Daniel Normolle,et al.  A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. , 2012, International journal of radiation oncology, biology, physics.

[2]  Jeffrey E. Lee,et al.  Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators , 2012, Cancer.

[3]  David Cella,et al.  Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Eslick,et al.  A Systematic Review and Meta-analysis of Survival and Surgical Outcomes Following Neoadjuvant Chemoradiotherapy for Pancreatic Cancer , 2011, Journal of Gastrointestinal Surgery.

[5]  Jongphil Kim,et al.  Neoadjuvant GTX Chemotherapy and IMRT‐based chemoradiation for borderline resectable pancreatic cancer , 2011, Journal of surgical oncology.

[6]  J. Tomlinson,et al.  Downstaging chemotherapy and alteration in the classic computed tomography/magnetic resonance imaging signs of vascular involvement in patients with pancreaticobiliary malignant tumors: influence on patient selection for surgery. , 2011, Archives of surgery.

[7]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[8]  Gang Li,et al.  Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. , 2011, Surgery.

[9]  G. Weiss,et al.  Preoperative Capecitabine and Concurrent Radiation for Borderline Resectable Pancreatic Cancer , 2011, Annals of Surgical Oncology.

[10]  G. Butturini,et al.  Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. , 2010, JAMA.

[11]  Kenneth J. Chang,et al.  Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement , 2009, Annals of Surgical Oncology.

[12]  Jeffrey E. Lee,et al.  Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Jeffrey E. Lee,et al.  Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Jeffrey E. Lee,et al.  Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. , 2008, Journal of the American College of Surgeons.

[15]  R. Abrams,et al.  Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. , 2008, JAMA.

[16]  T. Lawrence,et al.  Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells. , 2008, Translational oncology.

[17]  J. Berlin,et al.  Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Edgar Ben-Josef,et al.  Phase I study of oxaliplatin, full-dose gemcitabine, and concurrent radiation therapy in pancreatic cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Catrin Tudur Smith,et al.  Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Jeffrey E. Lee,et al.  Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy , 2006, Annals of Surgical Oncology.

[21]  P. Philip,et al.  A Multi-Institutional Phase II Trial of Preoperative Full-Dose Gemcitabine and Concurrent Radiation for Patients With Potentially Resectable Pancreatic Carcinoma , 2006, Annals of Surgical Oncology.

[22]  R. Labianca,et al.  Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Daniel Normolle,et al.  Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Strawderman,et al.  Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Tepper,et al.  Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. , 2001, International journal of gastrointestinal cancer.

[26]  B. Eisenberg,et al.  Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas , 2001, Journal of Gastrointestinal Surgery.

[27]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[28]  A. Piccoli,et al.  Recurrence after resection for ductal adenocarcinoma of the pancreas , 1997, World Journal of Surgery.

[29]  T. Lawrence,et al.  Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine. , 1996, International journal of radiation oncology, biology, physics.

[30]  F. Ames,et al.  Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. , 1992, Archives of surgery.

[31]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[32]  T. Eberlein.  Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial , 2008 .

[33]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[34]  C. Charnsangavej,et al.  Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. , 1994, American journal of surgery.